TY - JOUR
T1 - Delivering on the promise
T2 - Poly ADP ribose polymerase inhibition as targeted anticancer therapy
AU - O'Sullivan Coyne, Geraldine
AU - Chen, Alice
AU - Kummar, Shivaani
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/10/9
Y1 - 2015/10/9
N2 - Purpose of review: The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents. Recent findings: The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies. Summary: Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.
AB - Purpose of review: The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents. Recent findings: The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies. Summary: Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.
KW - BRCA1/2
KW - Chemopotentiation
KW - Combination strategies
KW - DNA damage repair
KW - Ovarian cancer
KW - Radiation sensitizer
UR - http://www.scopus.com/inward/record.url?scp=84944057623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944057623&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000238
DO - 10.1097/CCO.0000000000000238
M3 - Review article
C2 - 26447876
AN - SCOPUS:84944057623
SN - 1040-8746
VL - 27
SP - 475
EP - 481
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
IS - 6
ER -